Home LiteratureArticle Details
PMID: 9502078 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Clinical & experimental metastasis ·Vol. 16 ·No. 1 ·1998-01-00 ·Pages 62-73

Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM

Abstract

Expression of proteolytic parameters of the urokinase-type plasminogen activator (uPA) system [uPA receptor (uPA-R), plasminogen activator inhibitor (PAI)-1] has been proven to be an independent prognostic parameter in cancer. However, it has not been considered that the uPA system is interacting with several other protease/inhibitor systems, neither has a comparable prognostic role of these factors been investigated. Moreover, studies evaluating specific protease patterns indicating high individual risk are missing completely. Therefore, in a consecutive prospective series of 203 gastric cancer patients, the expression of activators (plasminogen, tPA, MMP-2, cathepsin D, antithrombin 3) and inhibitors (alpha-2-antiplasmin, alpha-2-macroglobulin, alpha-1-antitrypsin, alpha-1-antichymotrypsin) of proteolysis was studied immunohistochemically in the tumor epithelium semiquantitatively (score 0-3) in addition to the uPA system. Kaplan-Meier analysis (median time of follow-up 31 months) revealed a significant association of cathepsin D (P=0.0042), alpha-2-macroglobulin (P=0.0281) and antitrypsin (P=0.0372) with disease-free survival and of cathepsin D (P=0.0018), antitrypsin (P=0.0112) and antichymotrypsin (P=0.0002) with overall survival. Multivariate Cox analysis performed to correct these results for relative impact of the uPA system and established prognostic factors showed PAI-1 (disease-free survival: P=0.002, relative risk 1.86; overall survival: P=0.005, relative risk 1.39), pT and pN as independent parameters. Cathepsin D was shown to have an independent impact on disease-free survival (P=0.020, relative risk 2.98). Comparative chi-square analysis of cases with poor and good prognoses revealed that in patients with good clinical outcome, inhibitors of proteolysis are correlated significantly, whereas in patients with poor prognosis activators of proteolysis are significantly associated preferentially and significant correlations with the uPA-R are dominant. For detailed pattern analysis, stepwise overall Kaplan-Meier analyses were performed in subgroups of high uPA-R-, uPA-, PAI1- and cathepsin D expression for two additional proteases each. From these analyses, the combination of high (score 2/3) expression of uPA-R, PAI-1, antichymotrypsin and alpha-2-macroglobulin was identified as a high-risk pattern, representing parameters known to be essential for uPA-R internalization and recycling. This suggests some of the uPA-associated proteases and inhibitors investigated as univariate prognostic parameters in gastric cancer. Cathepsin D is a new independent parameter for disease-free survival. The study further demonstrates that a protease pattern promoting uPA-R recycling in tumor cells especially indicates high individual risk tumors in gastric cancer.

MeSH Terms
Adult Aged Aged, 80 and over Endopeptidases/metabolism Female Humans Immunohistochemistry Male Middle Aged Multivariate Analysis Neoplasm Proteins/metabolism Prognosis Protease Inhibitors/metabolism Risk Factors Statistics as Topic Stomach Neoplasms/diagnosis,metabolism,mortality Survival Analysis
Chemicals
Neoplasm Proteins Protease Inhibitors Endopeptidases
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Allgayer H
Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany.
Babic R
Grützner K U
Beyer B C
Tarabichi A
Schildberg F W
Heiss M M
References (39)
39 references, click to expand
  1. Tumor-associated alpha-2-macroglobulin in human melanomas.
    Int J Cancer. 1988 Mar 15;41(3):359-63 PMID: 2450069
  2. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
    Cancer Res. 1991 Jul 15;51(14):3690-5 PMID: 1648443
  3. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane.
    Mod Pathol. 1994 Feb;7(2):220-5 PMID: 8008747
  4. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
    Cancer Res. 1994 Jan 1;54(1):120-3 PMID: 8261432
  5. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
    FEBS Lett. 1992 Feb 3;297(1-2):112-8 PMID: 1551416
  6. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
    Cancer Res. 1990 Nov 1;50(21):6827-9 PMID: 2119883
  7. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.
    FEBS Lett. 1994 Feb 7;338(3):239-45 PMID: 8307187
  8. alpha2-Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver.
    Hepatology. 1996 Mar;23(3):560-70 PMID: 8617438
  9. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.
    Bioessays. 1993 Feb;15(2):105-11 PMID: 8385942
  10. Structure and function of the urokinase receptor.
    Blood Coagul Fibrinolysis. 1993 Apr;4(2):293-303 PMID: 8388742
  11. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
    Am J Pathol. 1991 May;138(5):1059-67 PMID: 1850957
  12. Secretion of alpha 2-macroglobulin, alpha 2-antiplasmin, and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture.
    J Neurosurg. 1990 Aug;73(2):234-41 PMID: 1694891
  13. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
    Gut. 1993 Jan;34(1):80-5 PMID: 8432457
  14. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.
    Cancer Res. 1986 Jan;46(1):1-7 PMID: 2998604
  15. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer.
    Cancer. 1993 May 1;71(9):2756-63 PMID: 8385566
  16. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
    Br J Cancer. 1977 Jan;35(1):1-39 PMID: 831755
  17. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
    Cancer Res. 1991 Aug 1;51(15):4067-71 PMID: 1855221
  18. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Hum Pathol. 1995 Oct;26(10):1133-8 PMID: 7557947
  19. The role of proteolytic enzymes in cancer invasion and metastasis.
    Clin Exp Metastasis. 1992 May;10(3):145-55 PMID: 1582084
  20. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    J Biol Chem. 1992 Jul 25;267(21):14543-6 PMID: 1378833
  21. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.
    Cell. 1991 Jan 25;64(2):327-36 PMID: 1703045
  22. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies.
    Int J Cancer. 1994 Feb 15;56(4):500-5 PMID: 8112886
  23. Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression.
    Cancer. 1995 Oct 15;76(8):1368-76 PMID: 8620411
  24. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
    J Cell Biol. 1991 Nov;115(4):1107-12 PMID: 1659573
  25. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.
    Eur J Surg Oncol. 1996 Feb;22(1):74-7 PMID: 8846873
  26. Relationship between plasminogen activators and stomach carcinoma stage.
    Acta Oncol. 1991;30(7):815-8 PMID: 1764272
  27. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.
    N Engl J Med. 1986 Dec 25;315(26):1650-9 PMID: 3537791
  28. In situ hybridization studies of alpha 2-macroglobulin receptor and receptor-associated protein in human prostate carcinoma.
    Prostate. 1996 May;28(5):311-7 PMID: 8610058
  29. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
    Int J Cancer. 1991 Apr 22;48(1):20-7 PMID: 1902201
  30. Defining the invasive phenotype of proximal gastric cancer cells.
    Cancer. 1994 Jan 1;73(1):22-7 PMID: 8275429
  31. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.
    J Biol Chem. 1986 Mar 15;261(8):3486-9 PMID: 3081506
  32. Activity of type IV collagenases in benign and malignant breast disease.
    Br J Cancer. 1993 May;67(5):1126-31 PMID: 8494711
  33. Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin.
    Biochemistry. 1985 Jul 16;24(15):3902-7 PMID: 2413880
  34. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
    Cancer Res. 1993 Apr 15;53(8):1911-5 PMID: 8385573
  35. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Breast Cancer Res Treat. 1993;24(3):195-208 PMID: 8435475
  36. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    J Clin Oncol. 1995 Aug;13(8):2084-93 PMID: 7636552
  37. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas.
    Int J Cancer. 1996 Feb 20;69(1):9-16 PMID: 8600068
  38. Serum acute phase reactants and prognosis in renal cell carcinoma.
    Cancer. 1995 Oct 15;76(8):1435-9 PMID: 8620420
  39. Cathepsin D and prognosis in breast cancer.
    N Engl J Med. 1990 Feb 1;322(5):297-302 PMID: 2296271
Article Info
Journal
Clinical & experimental metastasis
Abbr.
Clin Exp Metastasis
ISSN
0262-0898
Published
1998-01-00
Pages
62-73
Language
English
Region
Netherlands
NLM ID
8409970
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com